Agenus Inc. Amends 8-K Filing on Officer and Director Changes

Ticker: AGEN · Form: 8-K/A · Filed: Nov 8, 2024 · CIK: 1098972

Sentiment: neutral

Topics: amendment, corporate-governance, officer-changes, director-changes

TL;DR

Agenus Inc. is filing an amendment to its 8-K, updating info on who's running the show and how they're getting paid.

AI Summary

Agenus Inc. filed an 8-K/A on November 8, 2024, to amend a previous filing regarding events that occurred on August 8, 2024. The amendment pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. The company, formerly known as Antigenics Inc. /DE/, is incorporated in Delaware and headquartered in Lexington, Massachusetts.

Why It Matters

This amendment clarifies and potentially corrects information related to the company's leadership and executive compensation, which are critical for understanding corporate governance and financial health.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, primarily for clarification or correction, and does not appear to introduce new material risks.

Key Numbers

Key Players & Entities

FAQ

What specific information is being amended in the 8-K filing?

The 8-K/A amends information related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

What was Agenus Inc.'s former name?

Agenus Inc.'s former name was Antigenics Inc. /DE/.

On what date was the earliest event reported in the original filing?

The earliest event reported in the original filing was on August 08, 2024.

Where are Agenus Inc.'s principal executive offices located?

Agenus Inc.'s principal executive offices are located at 3 Forbes Road, Lexington, Massachusetts 02421.

What is the SEC file number for Agenus Inc.?

The SEC file number for Agenus Inc. is 000-29089.

Filing Stats: 476 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-08 16:05:08

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 8, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin, VP Finance

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on Read The Filing